

Rates of All-Cause and Mortality among Schizophrenic people living with and without HIV

Kalysha Closson^{1,2}, Kate Salters^{1,2}, Thomas L. Patterson³, Oghenowede Eyawo^{1,2}, Kiffer Card^{1,2}, William Chau¹, Monica Ye¹, Mark Hull¹, Viviane Lima^{1,4}, Julio S. G. Montaner^{1,4}, Robert S. Hogg^{1,2},
On behalf of the Comparative Outcomes and Service Utilization Trends (COAST) Cohort Study

1. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; 2. Simon Fraser University, Faculty of Health Sciences, Burnaby, BC, Canada; 3. University of California San Diego, Department of Psychiatry, San Diego, CA, USA; & 4. Division of AIDS, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

Background

- Despite significant advancements in antiretroviral therapy (ART) and improvements in life expectancy, people living with HIV (PLHIV), continue to be disproportionately affected by mental health concerns, including Schizophrenia (SZO).¹
- SZO is a mental health condition that has important implications for morbidity and mortality outcomes, with research demonstrating that people living with SZO face increased mortality outcomes.²
- As of yet, few studies have explored the impact that HIV and SZO have on mortality, and what factors are driving increased mortality among PLHIV living with concurrent SZO (HIV+/SZO+).

Methods

- The Comparative Outcomes and Service Utilization Trends (COAST) study is a population-based retrospective cohort study examining health outcomes and service use of PLHIV and a random 10% of the general population identified through a unique linkage with Population Data BC's individual-level longitudinal administrative databases
- Prevalence of SZO diagnosis was identified and calculated from 1998 to 2013, through physician billing and hospital-based administrative data using International Classification of Disease 9/10 codes
- Age and sex-adjusted all-cause and accident specific mortality rates were calculated among HIV+/SZO+, HIV-/SZO+, HIV+/SZO-, and HIV-/SZO-
- Two confounding models assessed 1. the independent association between SZO and Mortality among people living with HIV, and 2. HIV status and mortality among all people living with SZO
- Independent correlates of mortality was assessed among HIV+/SZO+

Results




Figure 1- Flow chart of study samples

References


1. Helleberg, M., Pedersen, M. G., Pedersen, C. B., Mortensen, P. B., & Obel, N. (2015). *Lancet HIV*, 2(8), e344-350. doi: 10.1016/S2352-3018(15)00089-2
 2. Allebeck, P. (1989). *Schizophr Bull*, 15(1), 81-89.
 3. Laursen, T. M., Nordentoft, M., & Mortensen, P. B. (2014). Excess early mortality in schizophrenia. *Annu Rev Clin Psychol*, 10, 425-448. doi: 10.1146/annurev-clinpsy-032813-153657

Results Continued

Table 1- Socio-demographic and health service use differences between HIV+/SZO+ and HIV-/SZO+

Characteristics	HIV+/SZO+ n= 843	HIV-/SZO+ n=5688	P-value
Age at baseline median (Q1, Q3)	37 (30-44)	36 (24-50)	0.07
Died by March 31 2013 (yes)	25.9%	18.0%	<0.001
Male Sex	75.1%	56.2%	<0.001
Substance use disorder (including alcohol) (yes)	89.4%	42.8%	<0.001
Ever on anti-psychotic meds (yes)	48.8%	38.8%	<0.001
Seen a psychiatrist at least once during the study period (yes)	70.1%	59.9%	<0.001

- Of 515,908 BC residents accessing medical services from 1998-2013 in our study sample, 2.6% (n=13,412) were PLHIV.
- Prevalence of SZO diagnosis during our study period was significantly higher among PLHIV compared to HIV-negative individuals (6.3% versus 1.1%, p<0.001).
- Compared to SZO+/HIV-, SZO+/HIV+ were significantly (all p<0.001) more likely to be male, have a concurrent substance use disorder, and ever be on anti-psychotic medication (Table 1).



	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
HIV-/SZO-	8,78	8,56	8,49	8,42	8,43	8,30	8,43	8,78	8,36	8,37	8,45	8,11	8,24	8,39	8,50	9,29
HIV-/SZO+	26,14	26,61	20,05	21,56	24,16	26,38	21,96	26,13	24,41	25,94	22,38	23,62	30,27	19,90	20,63	25,32
HIV+/SZO-	45,76	39,48	42,26	37,18	30,76	34,05	33,68	39,02	33,40	26,51	23,44	21,64	19,39	18,67	18,53	16,40
HIV+/SZO+	101,89	83,83	82,76	48,11	52,49	76,65	54,90	53,67	52,74	37,56	34,13	53,52	40,10	25,79	12,88	36,42

Figure 2- All-cause mortality and mortality rates from 1998 to 2013 among HIV-/SZO-, HIV-/SZO+, HIV+/SZO- and HIV+/SZO+

- All-cause mortality remained relatively stable throughout the study period for all groups, with the group with the highest mortality (HIV+/SZO+) showing a steady decline up until 2012.
- Mortality among the HIV+/SZO+ group may be increasing in more recent years
- Among all individuals with a SZO diagnosis during our study, PLHIV had a 2.62 times increased odds (95%CI=2.13-3.22) of mortality during the study period compared to those not living with HIV, after controlling for substance use disorder diagnosis and age at baseline.

Results Continued

Table 2- Unadjusted and adjusted factors associated with mortality among HIV+/SZO+

Characteristic	Died n%	Alive n%	Unadjusted Odds Ratio (95%CI)	Adjusted Odds Ratio
Age at COAST baseline median (Q1, Q3)	41 (34-48)	36 (29-42)	1.74 (1.48-2.05)	1.80 (1.51-2.15)
Sex				
Female	56 (25.7)	153 (24.5)	1.06 (0.75-1.52)	Not Included
Male	162 (74.3)	471 (75.5)	Ref	
Indigenous ancestry				
No	47 (21.6)	207 (33.2)	Ref	Ref
Yes	35 (16.1)	71 (11.4)	2.17 (1.30-3.63)	2.35 (1.36-4.05)
Unknown	136 (62.4)	346 (55.5)	1.73 (1.19-2.52)	1.86 (1.22-2.83)
Men who have sex with men				
No	87 (39.9)	258 (41.4)	Ref	Not Selected
Yes	30 (13.8)	130 (20.8)	0.68 (0.43-1.09)	
Unknown	101 (46.3)	236 (37.8)	1.27 (0.91-1.78)	
History of injection drug use				
No	55 (25.2)	157 (25.2)	Ref	Ref
Yes	163 (74.8)	467 (74.8)	1.00 (0.70-1.42)	1.62 (1.07-2.46)
AIDS ever				
No	142 (65.1)	425 (68.1)	Ref	Ref
Yes	45 (20.6)	88 (14.1)	1.53 (1.02-2.30)	1.68 (1.08-2.62)
Unknown	31 (14.2)	111 (17.8)	0.84 (0.54-1.30)	0.53 (0.32-0.86)
Ever on ART				
No	80 (36.7)	200 (32.1)	1.00	Not Selected
Yes	138 (63.3)	424 (67.9)	0.81 (0.59-1.12)	
Ever on anti-psychotic meds				
No	131 (60.1)	300 (48.1)	1.00	1.00
Yes	87 (39.9)	324 (51.9)	0.61 (0.45-0.84)	0.65 (0.46-0.92)
Ever had a psychiatry service code				
No	87 (39.9)	164 (26.3)	1.00	1.00
Yes	131 (60.1)	460 (73.7)	0.54 (0.39-0.74)	0.63 (0.44-0.91)

- Among HIV+/SZO+ Indigenous ancestry, history of injection drug use, ever having AIDS was associated with increased odds of mortality.
- Those who have ever been on anti-psychotic meds or had a psychiatric service code were at reduced odds of dying throughout the study period.

Discussion

- HIV+/SZO+ individuals appeared to be at the highest risk of mortality among all the subgroups examined in this study.
- Specific interventions should seek to improve the health and well-being of PLHIV concurrently living with severe mental health issues, including SZO.
- Our findings suggest, so as to reduce the excess burden of mortality among individuals with SZO, efforts should be targeted towards individuals of Indigenous ancestry, who have a history of substance use and are not adequately linked to HIV as well as psychiatric care.

Acknowledgements

Thank you to all the supportive staff at the BC Centre for Excellence in HIV/AIDS, and to Population Data BC for facilitating the linkage process. Thank you to Canadian Institute of Health Research for funding this project and to the the Ministry of Health BC and the institutional data stewards for granting access to the data.

Disclaimer: All inferences, opinions, and conclusions drawn in this poster are those of the authors, and do not reflect the opinions or policies of the data stewards or the funders

